atomoxetine / Generic mfg. - LARVOL DELTA

Symptomatic improvement in fibromyalgia after treatment of comorbid attention deficit hyperactivity disorder: a case report. (PubMed, J Med Case Rep) - "This case of a 33-year-old female with attention deficit hyperactivity disorder and chronic pain suspicious for fibromyalgia showed the improvement of pain symptoms with atomoxetine. While a few published cases have demonstrated a similar finding, this case is notable for the dramatic improvement and the response to a nonstimulant medication-atomoxetine. This case highlights the need for further research into the connection between attention deficit hyperactivity disorder and chronic pain, as well as the mechanism behind the effects of atomoxetine on pain."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Fibromyalgia • Musculoskeletal Pain • Pain • Psychiatry • Rheumatology

Targeting the mTOR Pathway with Natural Products: A Potential Therapeutic Approach for Autism Spectrum Disorders. (PubMed, Curr Neuropharmacol) - "Treatment for ASD symptoms typically includes stimulants, modafinil, atomoxetine, antidepressants, antipsychotics, and natural products. The mechanistic target of rapamycin (mTOR), a serine/threonine kinase, is dysregulated in many human diseases, leading to abnormal synapse formation, neuroinflammation, and mitochondrial dysfunction...mTORC1 and mTORC2 are key regulators of cellular processes, with mTORC1 being largely sensitive to nutrient availability and mTORC2 playing a crucial role in cell growth, proliferation, motility, and autophagy, which is modulated by the PI3K/Akt/mTOR pathway. Future research should examine the relationship between autism and the mTOR signaling pathway, as well as the phytochemicals that may contribute to improving the condition through this pathway."

Journal • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Inflammation • Metabolic Disorders • Psychiatry

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder. (PubMed, JCPP Adv) - "In fact, Atomoxetine response rates were found to be similar to those of methylphenidate in ASD studies, while inducing fewer adverse events and tolerated better. Further trials are warranted to make conclusive recommendations on Atomoxetine for improvement of common clinical symptoms of ADHD in the ASD pediatric population. Given limited approved therapies for common clinical symptoms of ASD in children and adolescents, Atomoxetine could be used as a safe off-label option due to a favorable tolerability profile and minimal adverse effects."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Depression • Developmental Disorders • Genetic Disorders • Mood Disorders • Pediatrics • Psychiatry

116130: Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinsons disease: a multi-center and multi-modal approach. (clinicaltrialsregister.eu) - P2/3 | N=20 | Recruiting | Sponsor: Stichting Radboud universitair medisch centrum | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

COST OF ADVERSE EVENT MANAGEMENT IN CHILDREN, ADOLESCENTS, AND ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE UNITED STATES (ISPOR 2026) - "Pairwise comparisons were conducted between centanafadine and each of lisdexamfetamine dimesylate, atomoxetine hydrochloride, viloxazine, methylphenidate hydrochloride, and guanfacine in children and adolescents, and each of lisdexamfetamine dimesylate, atomoxetine hydrochloride, viloxazine, and methylphenidate hydrochloride in adults. Centanafadine has the potential to reduce AE-related healthcare costs compared with alternative ADHD therapies for children, adolescents, and adults."

Adverse events • Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Bruxism in children and adolescents with attention deficit hyperactivity disorder due to medication regimen: prevalence, correlates, and consequences a cross-sectional study. (PubMed, Eur Oral Res) - "Common medications for ADHD include methylphenidate and atomoxetine. Bruxism is more common in males. Management of bruxism in children with ADHD should adopt a multidisciplinary approach integrating pharmacological, behavioral, and dental strategies."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Dental Disorders • Psychiatry

IDENTIFYING MEANINGFUL PATIENT SAVINGS ON GENERICS: DIRECT-TO-CONSUMER PRICES VS COMMERCIAL INSURANCE (ISPOR 2026) - "DTC pharmacies such as MCCPDC meaningfully lower out-of-pocket costs for higher-cost generic prescriptions which could otherwise be difficult to afford. Commercially insured patients should consider DTC pharmacies when their copayment or coinsurance for a generic medication exceeds $15, and particularly when it exceeds $100."

Clinical • Reimbursement • US reimbursement • CNS Disorders • Depression • Endocrine Disorders • Erectile Dysfunction • Multiple Sclerosis

Assessing the AOU Database for Vascular Complications of Prescribed Stimulants (AAN 2026) - "Objective: To assess the All of Us (AOU) Database for Vascular Dissections occurring in patients prescribed amphetamine, dextroamphetamine, atomoxetine, and methylphenidate.Background: Greater than 5% of the American population use prescribed stimulants, including Adderall. Limited conclusions can be assessed without further controlling for other prescriptions, co-morbidities, and risk factors for dissection. This study displays an elevated risk profile compared to the literature-reported incidence. We recommend further investigation of the effect of prescription stimulants on arterial dissection."

Atomoxetine and DAW2022 on OSA Severity (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jun 2024 ➔ Jun 2026 | Trial primary completion date: Jun 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Comparative Effects of Glp-1 Receptor Agonists and Atomoxetine-antimuscarinic Combinations (oxybutynin and Aroxybutynin) on Obstructive Sleep Apnea: A Scoping Review (ATS 2026) - No abstract available

Review • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Patient and public involvement and engagement in clinical trials at scale: Analysis of the first 3250 responses on the POrtal for Patient and Public Engagement in Dementia (POPPED). (PubMed, Alzheimers Dement) - "Web-based PPIE can effectively inform dementia research at scale and provides a reusable resource for other studies."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Atomoxetine suppresses nitric oxide synthesis induced by lipopolysaccharide in BV-2 microglia cells through the modulation of STAT1 and STAT3. (PubMed, Neuroscience) - "Conversely, while total STAT3 expression was reduced, its phosphorylation ratio increased, reflecting a more complex regulatory interaction. Collectively, these findings suggested that ATX exerts multifaceted effects on key inflammatory signaling pathways, notably modulating iNOS expression through simultaneous regulation of the STAT1 and STAT3."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Inflammation • Psychiatry • NFKBIA • STAT1 • STAT3

AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Radboud University Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Pharmacological management of attention deficit hyperactivity disorder in adults. (PubMed, Aust Prescr) - "The main pharmacotherapies for adults with ADHD include psychostimulants, such as methylphenidate and amphetamines (dexamfetamine and lisdexamfetamine), and non-psychostimulants such as atomoxetine. Individuals prescribed ADHD drugs should be monitored for both physical (e.g. cardiac symptoms, appetite changes, seizures) and psychiatric (e.g. mood disturbances, anxiety, psychosis) adverse effects. While pharmacological treatment is effective for adults with ADHD, it should be integrated into a broader, multidisciplinary approach that also includes nonpharmacological strategies such as psychological therapies and allied health support."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Mood Disorders • Psychiatry

Differentiating atomoxetine-induced agitation from mania relapse in a patient with bipolar disorder and ADHD: a case report. (PubMed, J Psychiatry Neurosci) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Construction of Chiral β-Boryl Aldehydes via Asymmetric Hydroformylation of 1,1-Disubstituted Alkenyl Boronates. (PubMed, Org Lett) - "Scale-up studies delivered TON of up to 4050, underscoring the robustness and practical utility of the method. The synthetic value of the resulting bifunctional products is further showcased through concise derivatizations and formal syntheses of (S)-Fluoxetine and (R)-Atomoxetine, highlighting their potential as versatile, densely functionalized building blocks for complex molecule construction."

Journal

Clinical Features of Adults With Attention Deficit/Hyperactivity Disorder, Focusing on Their Adherence to Medication. (PubMed, Psychiatry Investig) - "ADHD not only persists into adulthood but is associated with a wide range of psychiatric symptoms and comorbidities. Clinicians should constantly consider the possibility of ADHD when evaluating adult patients. Most importantly, greater emphasis should be placed on improving adherence to pharmacological treatment rather than on the relatively minimal risk of medication abuse or misuse. Enhancing treatment adherence in adults with ADHD has the potential to significantly improve functioning across multiple domains."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Recent Advances in Pharmacological Management of Autism: A Narrative Review. (PubMed, Cureus) - "Medications, including US Food and Drug Administration (FDA)‑approved antipsychotics such as risperidone and aripiprazole, are used to manage comorbid irritability and aggression, stimulants and non‑stimulants (e.g., methylphenidate, atomoxetine, clonidine, guanfacine) to treat ADHD-like symptoms, and melatonin for sleep disturbances. Other off‑label agents like selective serotonin reuptake inhibitor (SSRIs) for anxiety/obsessive compulsive disorder (OCD), anticonvulsants or mood stabilizers for mood dysregulation. Emerging compounds such as intranasal oxytocin and N‑acetylcysteine are under investigation but have not yet been formally approved. The future of ASD care hinges on the development of objective, biologically based diagnostic tools ranging from EEG and neuroimaging biomarkers to proteomic and metabolomic panels that could enable early, precise identification and guide personalized treatment strategies."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Depression • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Sleep Disorder

Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study. (PubMed, Lancet Reg Health Eur) - "We estimated the prevalence and incidence of methylphenidate, dexamphetamine, lisdexamfetamine, atomoxetine and guanfacine use among individuals aged 3 years and older. Understanding the utilisation of ADHD medications can provide useful information in monitoring use, as well as for anticipation and planning to minimise potential shortages. European Medicines Agency."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Chronic Administration of Atomoxetine and Methylphenidate Induces Differential Alterations in the Hippocampus and Striatum of Young Rats. (PubMed, Neurotox Res) - No abstract available

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD. (PubMed, Pharmacol Ther) - "Treatment emphasizes multimodal approaches, with stimulants as first-line pharmacotherapy due to their superior efficacy over non-stimulants like atomoxetine and viloxazine. Novel agents in development, such as centanafadine triple reuptake inhibitor and solriamfetol target core symptoms and comorbidities, showing promising phase III results...Psychotherapeutic options, particularly cognitive-behavioral therapy (CBT)-based interventions, improve symptom management and emotional regulation, often as adjuncts to medication. The review highlights the need for personalized strategies addressing adherence, comorbidity, and long-term outcomes, emphasizing integrated care to mitigate ADHD's lifelong impact."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drug-related suicidal events in children and teenagers: Age-stratified insights from FAERS. (PubMed, Leg Med (Tokyo)) - "Across FAERS youth suicide reports, drug-associated fatality risk varies markedly by drug, surges in mid- to late adolescence, diverges by sex and shifts at both age extremes. These heterogeneities underscore the need for age-appropriate pharmacovigilance and trial strategies rather than direct extrapolation from adult data, particularly regarding the safety of drugs associated with suicide."

Journal • Pediatrics

Atomoxetine for encopresis in children with autism spectrum disorder: Report of 4 cases. (PubMed, Psychiatr Danub) - No abstract available

Journal • Autism Spectrum Disorder • Genetic Disorders

Efficacy and safety of atomoxetine in the treatment of ADHD in children and adolescents: a systematic review. (PubMed, Front Child Adolesc Psychiatry) - "Atomoxetine demonstrated comparable efficacy to methylphenidate in reducing ADHD symptoms. Continued research, especially long-term studies, is necessary to confirm its efficacy across different patient subgroups. Identifier CRD420251152121."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Psychiatry